Press Release

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis

Scope of the Report:

This report focuses on the Xeljanz (tofacitnib) Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Xeljanz (tofacitnib) Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.


Get Free sample Report @ https://www.wiseguyreports.com/sample-request/3442355-global-xeljanz-tofacitnib-drug-market-2018-by-manufacturers


Market Segment by Manufacturers, this report covers


Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers


Extended-release Tablets

Market Segment by Applications, can be divided into

Rheumatoid Arthritis

Psoriatic Arthritis


Complete Report Details https://www.wiseguyreports.com/reports/3442355-global-xeljanz-tofacitnib-drug-market-2018-by-manufacturers


Table of Contents -Major Key Points

1 Market Overview

1.1 Xeljanz (tofacitnib) Drug Introduction

1.2 Market Analysis by Type

1.2.1 Tablets

1.2.2 Extended-release Tablets

1.3 Market Analysis by Applications

1.3.1 Rheumatoid Arthritis

1.3.2 Psoriatic Arthritis

1.3.3 Other

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico) United States Market States and Outlook (2013-2023) Canada Market States and Outlook (2013-2023) Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Germany Market States and Outlook (2013-2023) France Market States and Outlook (2013-2023) UK Market States and Outlook (2013-2023) Russia Market States and Outlook (2013-2023) Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) China Market States and Outlook (2013-2023) Japan Market States and Outlook (2013-2023) Korea Market States and Outlook (2013-2023) India Market States and Outlook (2013-2023) Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa Brazil Market States and Outlook (2013-2023) Egypt Market States and Outlook (2013-2023) Saudi Arabia Market States and Outlook (2013-2023) South Africa Market States and Outlook (2013-2023) Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force


2 Manufacturers Profiles

2.1 Pfizer

2.1.1 Business Overview

2.1.2 Xeljanz (tofacitnib) Drug Type and Applications Product A Product B

2.1.3 Pfizer Xeljanz (tofacitnib) Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)



Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com